In a small Houston clinic, more than a decade ago, patients with advanced cancer were receiving treatments that used radioactive molecules to seek out tumors and destroy them from within using an approach that would eventually help reshape oncology.
Newco Idel Therapeutics GmbH has closed a €9 million (US$10.4 million) seed round to advance the development of a technology for delivery of cytotoxic drugs directly into the cytosol of tumor cells.
Uppthera Inc. has patented new NLRP3 inflammasome inhibitors potentially useful for the treatment of cancer, metabolic and autoimmune diseases, cardiovascular, inflammatory, neurological, renal and respiratory disorders, among others.
Ensem Therapeutics Inc. has divulged new bicyclic heteroaryl and heterocyclic compounds acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer.
The Scripps Research Institute has discovered new bicyclo[1.1.1]pentane-based DNA topoisomerase inhibitors and antibody-drug conjugates comprising a monoclonal antibody covalently linked to a DNA topoisomerase inhibitor. They are described as potentially useful for the treatment of cancer.
Bolt Biotherapeutics Inc. has prepared and tested new immunoconjugates comprising antibodies covalently linked to stimulator of interferon genes protein (STING; TMEM173) agonists. They are designed for potential use in the treatment of cancer.
Researchers from the Chinese Academy of Sciences reported the design and preclinical characterization of YCH-3971, a selective PARP1 inhibitor developed for the treatment of BRCA-mutated tumors.
CAR T-cell therapy can be applied to treat some chronic infectious diseases, particularly to provide a functional cure for HIV-1 in people living with HIV. However, the effectiveness of CAR T cells for persistent suppression of HIV still faces many constraints, including the high mutation rate of reverse transcriptase, which enables the emergence of immune escape viral variants.
The U.S. FDA has issued a final order to reclassify optical diagnostic devices for melanoma detection and electrical impedance spectrometers from class III to class II, with special controls required.
RSS
